3/22
08:00 pm
hcm
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
Low
Report
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
3/11
09:06 pm
hcm
HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ... [Yahoo! Finance]
Medium
Report
HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ... [Yahoo! Finance]
3/10
03:37 pm
hcm
HUTCHMED (HCM) had its price target lowered by Bank of America Corporation from $21.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
HUTCHMED (HCM) had its price target lowered by Bank of America Corporation from $21.00 to $20.00. They now have a "buy" rating on the stock.
3/9
05:30 am
hcm
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
Low
Report
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
3/6
03:30 am
hcm
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
Low
Report
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
3/5
09:32 pm
hcm
HUTCHMED H2 Earnings Call Highlights [Yahoo! Finance]
Low
Report
HUTCHMED H2 Earnings Call Highlights [Yahoo! Finance]
3/5
06:00 am
hcm
HUTCHMED Reports 2025 Full Year Results and Business Updates
Low
Report
HUTCHMED Reports 2025 Full Year Results and Business Updates
3/4
03:30 am
hcm
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
Low
Report
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
2/6
03:30 am
hcm
HUTCHMED to Announce 2025 Final Results
Medium
Report
HUTCHMED to Announce 2025 Final Results
1/20
06:59 am
hcm
HUTCHMED (NASDAQ:HCM) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Low
Report
HUTCHMED (NASDAQ:HCM) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
1/13
11:00 pm
hcm
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
Low
Report
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
1/6
07:00 pm
hcm
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Medium
Report
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
1/4
07:00 pm
hcm
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
Low
Report
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma